Compare ZJYL & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | SER |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | United States |
| Employees | N/A | 13 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 18.1M |
| IPO Year | 2020 | N/A |
| Metric | ZJYL | SER |
|---|---|---|
| Price | $0.15 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 511.0K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $1.55 |
| 52 Week High | $1.03 | $7.92 |
| Indicator | ZJYL | SER |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 32.66 |
| Support Level | $0.13 | N/A |
| Resistance Level | $0.16 | $3.10 |
| Average True Range (ATR) | 0.01 | 0.25 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 45.45 | 2.09 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.